Werewolf Therapeutics, Inc.
HOWL
$0.7998
-$0.0702-8.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.14M | 1.89M | 3.39M | 9.28M | 16.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.14M | 1.89M | 3.39M | 9.28M | 16.22M |
| Cost of Revenue | 52.50M | 52.20M | 46.59M | 44.90M | 39.22M |
| Gross Profit | -51.35M | -50.31M | -43.21M | -35.62M | -23.00M |
| SG&A Expenses | 23.07M | 23.28M | 23.00M | 22.71M | 22.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.57M | 75.48M | 69.59M | 67.62M | 61.66M |
| Operating Income | -74.42M | -73.59M | -66.21M | -58.34M | -45.44M |
| Income Before Tax | -72.41M | -70.52M | -62.12M | -53.73M | -41.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.41 | -70.52 | -62.12 | -53.73 | -41.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.41M | -70.52M | -62.12M | -53.73M | -41.58M |
| EBIT | -74.42M | -73.59M | -66.21M | -58.34M | -45.44M |
| EBITDA | -72.65M | -71.78M | -64.38M | -56.51M | -43.64M |
| EPS Basic | -1.64 | -1.63 | -1.50 | -1.35 | -1.09 |
| Normalized Basic EPS | -1.02 | -1.01 | -0.93 | -0.83 | -0.68 |
| EPS Diluted | -1.67 | -1.65 | -1.52 | -1.38 | -1.09 |
| Normalized Diluted EPS | -1.01 | -1.01 | -0.92 | -0.83 | -0.68 |
| Average Basic Shares Outstanding | 176.53M | 173.31M | 165.40M | 157.35M | 149.39M |
| Average Diluted Shares Outstanding | 177.05M | 173.83M | 165.93M | 157.87M | 149.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |